Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).
Howard M. Sandler(Cedars-Sinai Medical Center), Felix Y. Feng(University of Michigan), Thomas Wiegel(University Hospital Ulm), Suneel Mundle(Johnson & Johnson (United States)), Bertrand Tombal(Cliniques Universitaires Saint-Luc), David P. Dearnaley(Royal Marsden NHS Foundation Trust), Stephen J. Freedland(Cedars-Sinai Medical Center), Sabine Brookman‐May(Ludwig-Maximilians-Universität München), Adam P. Dicker(Thomas Jefferson University Hospital), Rosamerlinda S. Rosales(Janssen (United States)), Marika Ciprotti(Janssen (Belgium)), Anders Widmark(Umeå University), Neal D. Shore(Carolina Urologic Research Center), Michael McKenzie(Provincial Health Services Authority), Alberto Bossi(Institut Gustave Roussy), Sharon McCarthy(Janssen (United States)), Jennifer Anne Whalen(Janssen (United States)), Jason Martin(Janssen (United Kingdom)), Branko Miladinović
Cited by 9
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k